Small molecule-based RDC (Radionuclide Drug Conjugate), a new type of drug for cancer treatment, has received a lot of attention. The conjugation of radionuclide-small molecule is a very professional process.

As a top CRO company, Rdcthera can provide a high-quality radionuclide-small molecule conjugation service for you.

Radionuclide Small Molecule Conjugation The most widely developed small molecule-based RDC is the one targeting the PSMA (Prostate-Specific Membrane Antigen), a type-II transmembrane glycoprotein with several enzymatic functions overexpressed in prostate cancer. Prostate cancer is the second most prevalent type of cancer among men worldwide. The PSMA-directed radiopharmaceuticals are now used extensively for diagnostic imaging and treatment.